ACE and metabolic dysfunction-associated steatotic liver disease: The percentage of patients with T2DM was higher in the group with NAFLD (n = 28, 87.5%) than in the group without NAFLD (n = 4, 12.5%) (p = 0.04); no differences were found in the prevalence of high BP, use of ACE inhibitors or ARBs, smoking habits, and alcohol consumption between the two groups.